Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. Aceves-Luquero CI, et al. Among authors: deininger mw. PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124. PLoS One. 2009. PMID: 19568437 Free PMC article.
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. O'Hare T, et al. Among authors: deininger mw. Blood. 2011 Nov 10;118(19):5250-4. doi: 10.1182/blood-2011-05-349191. Epub 2011 Sep 8. Blood. 2011. PMID: 21908430 Free PMC article.
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ. O'Hare T, et al. Among authors: deininger mw. Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10. Cancer Res. 2013. PMID: 23576564 Free PMC article.
Resistance to imatinib: mutations and beyond.
La Rosée P, Deininger MW. La Rosée P, et al. Among authors: deininger mw. Semin Hematol. 2010 Oct;47(4):335-43. doi: 10.1053/j.seminhematol.2010.06.005. Semin Hematol. 2010. PMID: 20875550 Review.
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. Agarwal A, et al. Among authors: deininger mw. Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29. Leukemia. 2008. PMID: 18509354 No abstract available.
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Agarwal A, et al. Among authors: deininger j, deininger mw. Blood. 2008 Sep 1;112(5):1960-70. doi: 10.1182/blood-2007-09-113860. Epub 2008 Jun 17. Blood. 2008. PMID: 18559973 Free PMC article.
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW. Agarwal A, et al. Among authors: deininger mw. Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7. Blood. 2014. PMID: 25293778 Free PMC article.
261 results